Company Filing History:
Years Active: 2017
Title: Innovations in Peptide Manufacturing by Jon Holbech Rasmussen
Introduction
Jon Holbech Rasmussen is a prominent inventor based in Lyngby, Denmark. He has made significant contributions to the field of peptide manufacturing, particularly through his innovative processes. With one patent to his name, Rasmussen has demonstrated his expertise and creativity in the pharmaceutical industry.
Latest Patents
Rasmussen's notable patent is titled "Process for the manufacture of degarelix and its intermediates." This invention relates to a comprehensive liquid-phase manufacturing process designed to prepare the decapeptide Degarelix, along with its protected precursors and other useful intermediates. The patent outlines innovative methods to obtain Degarelix by treating a Degarelix precursor with a cleaving agent in an organic solvent. This process not only enhances the efficiency of manufacturing Degarelix but also details the purification techniques of the peptide itself.
Career Highlights
Currently, Jon Holbech Rasmussen is associated with Ferring B.V., a global biopharmaceutical group known for its focus on urology, reproductive health, and gastroenterology. His work at Ferring B.V. allows him to participate actively in the development of groundbreaking pharmaceutical solutions, particularly in the area of peptide drugs.
Collaborations
Throughout his career, Rasmussen has collaborated with esteemed colleagues such as Jens Fornsgaard and Stefan Hansen. Their combined expertise and shared vision for advancing peptide technology have contributed to innovative solutions in the pharmaceutical landscape.
Conclusion
Jon Holbech Rasmussen stands out as an influential figure in peptide manufacturing. His dedication to innovation and collaboration continues to drive advancements in the field, particularly through his patent on the manufacturing process of Degarelix. As the industry evolves, Rasmussen’s contributions are likely to pave the way for future breakthroughs in peptide-based therapeutics.